Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541552 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL6492774 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL25831748 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186548 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL15154705 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL2599515 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186572 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL20262054 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186565 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186569 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-118541370-A | Azaindole derivatives and their use as ERK kinase inhibitors | AGV探索公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| US-5017619-A | Anitdiabetic | HOFFMANN-LA ROCHE INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0130069-B1 | HEXAHYDROPYRROLO (2,1-A) ISOQUINOLINE DERIVATIVES | McNeilab, Inc. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4719216-A | Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants | MCNEILAB, INC. (US) | 1988-01-12 | — | — | US | disclosed |
| US-4595688-A | Hexahydropyrrolo[2,1-a]isoquinoline derivatives and antidepressant use thereof | MCNEILAB, INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4588749-A | ANTIOBESITY AND HYPOGLYCEMIC AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-05-13 | — | — | US | disclosed |
| US-4585796-A | HYPOGLYCEMIC, ANTI-OBESITY | HOFFMANN-LA ROCHE INC. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0130069-A2 | Hexahydropyrrolo (2,1-a) isoquinoline derivatives | McNeilab, Inc. (US) | 1985-01-02 | — | — | EP | disclosed |
| EP-0040000-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | HTR1A 2671/4885HTR2B 2102/4885CHRM2 2451/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | HTR1A 4089/4885HTR2B 4597/4885CHRM2 3639/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | HTR1A 2671/4885HTR2B 2102/4885CHRM2 2451/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | HTR1A 2671/4885HTR2B 2102/4885CHRM2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.